This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Black Tea on Vascular Function (Heraclitus)

This study has been completed.
Sponsor:
Collaborator:
Sprim Advanced Life Sciences
Information provided by (Responsible Party):
Unilever R&D
ClinicalTrials.gov Identifier:
NCT01945970
First received: September 8, 2013
Last updated: February 17, 2017
Last verified: February 2017
  Purpose
Epidemiological studies indicate that regular consumption of three cups of black tea per day reduces the risk of stroke or myocardial infarction. In a number of previous nutrition intervention studies tea has been shown to improve vascular function as assessed by Flow Mediated Dilation (FMD).

Condition Intervention
Vascular Function Other: Black tea extract Other: Positive control Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Randomized Double Blind Placebo Controlled Crossover Study to Assess the Effect of Black Tea on Flow-Mediated Dilation in Healthy, Non-tea Drinking Males

Resource links provided by NLM:


Further study details as provided by Unilever R&D:

Primary Outcome Measures:
  • Flow Mediated Dilation, Acute-upon-chronic, Black Tea [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 8. ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).


Secondary Outcome Measures:
  • Flow Mediated Dilation, Acute, Black Tea [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 1 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Flow Mediated Dilation, Chronic, Black Tea [ Time Frame: From before consumption day 1 to before consumption day 8. ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Flow Mediated Dilation, Acute-upon-chronic, Positive Control [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 8 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Flow Mediated Dilation, Acute, Positive Control [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 1 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Flow Mediated Dilation, Chronic, Positive Control [ Time Frame: From before consumption on day 1 to before consumption day 8 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).


Other Outcome Measures:
  • Systolic Blood Pressure, Black Tea [ Time Frame: From before consumption on day 1 to before consumption on day 8 ]
    Change in Systolic blood pressure

  • Diastolic Blood Pressure Black Tea [ Time Frame: From before consumption on day 1 to before consumption day 8 ]
    Change in Diastolic blood pressure

  • Systolic Blood Pressure, Positive Control [ Time Frame: From before consumption (baseline) day 1 to before consumption day 8 ]
    Change in systolic blood pressure

  • Diastolic Blood Pressure, Positive Control [ Time Frame: From before consumption on day 1 to before consumption day 8 ]
    Change in Diastolic Blood pressure

  • Endothelium Independent Dilation, Acute-upon-chronic, Black Tea [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 8 ]

    FMD measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Endothelium Independent Dilation, Chronic, Black Tea [ Time Frame: From before consumption on day 1 to before consumption day 8 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Endothelium-Independent Dilation, Acute, Black Tea [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 1 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Endothelium Independent Dilation, Acute-upon-chronic, Positive Control [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 8 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Endothelium Independent Dilation, Chronic, Positive Control [ Time Frame: From before consumption on day 1 to before consumption day 8 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).

  • Endothelium Independent Dilation, Acute, Positive Control [ Time Frame: From before consumption on day 1 to 2 hours post consumption on day 1 ]

    Flow mediated dilation (FMD) measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (Resting stage)
    • 5 minutes of forearm occlusion at 300±30 mmHg (cuff occlusion stage), just below the elbow 2-5 cm from antecubital crease)
    • 4 minutes FMD scan, which started immediately after release of occlusion (reactive hyperaemia stage)
    • When the artery had returned to baseline a second 1 minute scan was taken
    • 25 µg sublingual glyceryl trinitrate (GTN) was given to the subject
    • 5 minutes GTN scan to assess the endothelium-independent dilation FMD and response to GTN was calculated as maximal percent increase in diameter above baseline (mean value of measures obtained during 1 minute before cuff inflation).


Enrollment: 30
Study Start Date: September 2013
Study Completion Date: December 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Black tea extract
Spray dried aqueous extract of a representative batch of black tea
Other: Black tea extract
Black tea extract
Active Comparator: Positive control
Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
Other: Positive control
Positive control
Placebo Comparator: Placebo
Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
Other: Placebo
Placebo

Detailed Description:
The current study tests a specific Black tea extract against a placebo in population that has previously show to be sensitive to the effect of black tea on Flow Mediated dilation. A tea extract that has previously been shown to improve FMD is included as the positive control.
  Eligibility

Ages Eligible for Study:   40 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Apparently healthy male volunteers with no history of cardiovascular disease
  • Having body mass index (BMI) of between 18.0 and 30.0 kg/m2 (inclusive)
  • Non-smokers (> 2 years)
  • Non-tea drinkers (less or equal 1 cup/week)
  • Limited alcohol intake (less or equal 21 units/week)
  • Systolic blood pressure less or equal 160 mmHg and/or diastolic blood pressure less or equal 100 mmHg at screening
  • Brachial artery can be imaged using ultrasound and at screening FMD value is within the expected range as judged by the PI
  • Judged to be in good health on the basis of medical history, physical examination and routine laboratory tests (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, highly sensitive C-reactive protein).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01945970

Locations
Italy
Azienda Ospedaliero-Universitaria Pisana, Centro di Farmacologia Clinicaper la Sperimentazione dei Farmaci
Pisa, Italy
Sponsors and Collaborators
Unilever R&D
Sprim Advanced Life Sciences
Investigators
Principal Investigator: Lorenzo Ghiadoni, MD University of Pisa, Internal medicine
  More Information

Responsible Party: Unilever R&D
ClinicalTrials.gov Identifier: NCT01945970     History of Changes
Other Study ID Numbers: REF-BEV-1134
Study First Received: September 8, 2013
Results First Received: December 23, 2016
Last Updated: February 17, 2017

Keywords provided by Unilever R&D:
Vascular function
Flow mediated dilation
Tea

ClinicalTrials.gov processed this record on September 20, 2017